INT182643

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2004
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 13.12
Pain Relevance 1.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (TNFSF11) extracellular space (TNFSF11) extracellular region (TNFSF11)
plasma membrane (TNFSF11) intracellular (TNFSF11) response to stress (TNFSF11)
Anatomy Link Frequency
osteoclast 8
macrophage 2
precursor cells 1
TNFSF11 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 61 100.00 Very High Very High Very High
rheumatoid arthritis 4 96.60 Very High Very High Very High
Arthritis 12 93.84 High High
Inflammation 44 89.32 High High
Osteoarthritis 209 88.60 High High
cva 28 88.52 High High
fibrosis 110 88.24 High High
Pain 23 73.92 Quite High
metalloproteinase 13 64.64 Quite High
Inflammatory response 1 62.64 Quite High
Disease Link Frequency Relevance Heat
Osteoporosis 515 99.28 Very High Very High Very High
Metastasis 280 99.26 Very High Very High Very High
Cancer 232 98.40 Very High Very High Very High
Necrosis 18 98.16 Very High Very High Very High
Hypercalcemia 140 97.36 Very High Very High Very High
Rheumatoid Arthritis 4 96.60 Very High Very High Very High
Systemic Lupus Erythematosus 5 96.08 Very High Very High Very High
Apoptosis 32 95.76 Very High Very High Very High
Dermatomyositis 3 94.64 High High
Juvenile Chronic Polyarthritis 3 93.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the other hand, OPG is considered a decoy receptor that blocks the binding of RANKL to the RANK receptor, located on osteoclast precursors, thereby inhibiting the terminal stage of osteoclastic differentiation and suppressing its activation as well as inducing the apoptosis of mature osteoclasts.
RANKL Binding (binding) of in osteoclast associated with osteoporosis and apoptosis
1) Confidence 0.35 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 1.23 Pain Relevance 0.29
RANK-RANKL interaction in the presence of macrophage colony-stimulating factor activates multiple intracellular signaling cascades (nuclear factor-?
RANKL Binding (interaction) of in macrophage
2) Confidence 0.28 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.69 Pain Relevance 0
B (RANK) ligand (RANKL), are known to induce the differentiation of monocytes/macrophages into osteoclasts; whereas osteoprotegerin (OPG), a soluble decoy receptor for RANKL that competes with RANK for RANKL binding, is known to suppress differentiation [1, 2].
RANKL Binding (binding) of in osteoclasts
3) Confidence 0.28 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2829618 Disease Relevance 0.16 Pain Relevance 0.08
OPG is a negative regulator of the RANK/RANKL pathway and prevents RANK-RANKL interaction by sequestering RANKL.
RANKL Binding (interaction) of
4) Confidence 0.22 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.76 Pain Relevance 0.04
A prior study in our laboratory using a mouse intratibial injection model of metastasis demonstrated that blocking the RANK-RANKL interaction by RANK-Fc (a recombinant soluble fusion protein consisting of extracellular domain of RANK coupled with the Fc domain of human IgG) limits the formation of osteolytic bone lesions [44].
RANKL Binding (interaction) of associated with metastasis
5) Confidence 0.21 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.32 Pain Relevance 0.04
-MAPK is activated in human osteoclast precursor cells upon binding of RANKL, which indicates a possible role for p38?
RANKL Binding (binding) of in precursor cells
6) Confidence 0.20 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991031 Disease Relevance 0.73 Pain Relevance 0.57
RANKL, in turn, binds to its receptor, RANK, on osteoclast lineage cells.
RANKL Binding (binds) of in osteoclast
7) Confidence 0.18 Published 2004 Journal International Journal of Medical Sciences Section Body Doc Link PMC1074710 Disease Relevance 0.61 Pain Relevance 0
Cytokines produced by immune cells (eg, RANKL, macrophage colony-stimulating factor, tumor necrosis factor alpha [TNF-?]
RANKL Binding (immune cells) of in macrophage associated with necrosis, cancer and cytokine
8) Confidence 0.17 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2946855 Disease Relevance 1.51 Pain Relevance 0.28
Denosumab is a fully human monoclonal antibody to rankl; it binds to human rankl, thus preventing osteoclast activation and subsequently reducing bone resorption.
rankl Binding (binds) of in osteoclast associated with hypercalcemia
9) Confidence 0.15 Published 2008 Journal Current Oncology Section Body Doc Link PMC2216420 Disease Relevance 0.41 Pain Relevance 0.04
Specifically, it enhances the osteoblastic production of osteoprotegerin, which has anti-osteoclastic properties because of its ability to bind to rankl and subsequently to block the rankl/rank interaction required for osteoclast recruitment and activation 59,60.
rankl Binding (interaction) of in osteoclast associated with osteoporosis
10) Confidence 0.15 Published 2008 Journal Current Oncology Section Body Doc Link PMC2216420 Disease Relevance 0.98 Pain Relevance 0
OPG competitively inhibits the binding of RANKL to RANK on osteoclasts and their precursors.
RANKL Binding (binding) of in osteoclasts
11) Confidence 0.14 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.84 Pain Relevance 0
This antibody, named denosumab, has been shown to specifically bind to RANKL with a very high affinity, preventing its interaction with the receptor RANK.
RANKL Binding (bind) of
12) Confidence 0.13 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.66 Pain Relevance 0
Factors recognized to be responsible for these effects are various cytokines and GC use, especially via the RANK-RANKL-OPG system.
RANKL Binding (recognized) of associated with cytokine
13) Confidence 0.11 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2768686 Disease Relevance 1.95 Pain Relevance 0.10
RANKL stimulates osteoclastogenesis and osteoclast function by binding to the cell surface RANK located on osteoclast precursors and osteoclasts – the interaction necessary for the formation of osteoclasts, osteoclast survival, and bone resorption [35-37].
RANKL Binding (binding) of in osteoclast associated with hypercalcemia
14) Confidence 0.11 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2483463 Disease Relevance 0.41 Pain Relevance 0.03
Denosumab inhibits the maturation of osteoclasts by binding to RANKL [85].
RANKL Binding (binding) of in osteoclasts
15) Confidence 0.08 Published 2011 Journal Journal of Osteoporosis Section Body Doc Link PMC3010683 Disease Relevance 0.88 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox